Vanguard Capital Management’s BioNTech BNTX Stock Holding History

Vanguard Capital Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19K	Buy	+204	New	+$19.2K	﹤0.01%	4013

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management's BNTX Position: Q2 2026 in Review

Vanguard Capital Management opened a new position in BioNTech (BNTX) in Q2 2026: 204 shares worth $19K. The stake represents ﹤0.01% of the portfolio and ranks #4013 among its holdings.

279 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Vanguard Capital Management held 204 shares of BioNTech worth $19K as of Q2 2026.
BioNTech was a new Vanguard Capital Management position in Q2 2026.
BioNTech made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #4013 holding.
279 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.